Published with kind permission of MEDNOUS UCB SA achieved its revenue and earnings targets for 2011, while declaring that a period of sustained growth lies ahead as its off-patent medicines are replaced by new propr... more »
Published with kind permission of MEDNOUS Two Russian oligarchs are making a second bid to buy the Danish antibody developer, Affitech A/S, after their first bid failed to give them the 90% ownership required to take t... more »
Published with kind permission of MEDNOUS Ablynx NV suffered the slings and arrows of outrageous fortune in 2011 as it achieved clinical proof of concept for the first time for one of its platform products, only to fin... more »
Published with kind permission of MEDNOUS Addex Pharmaceuticals Ltd expects to report top-line data at the end of March for its lead allosteric modulator that is being developed to treat patients with Parkinson’s disea... more »
Looking for special service?
Don't spend time on search!
Get applications from providers For Free